Stock Earnings

Question 1

¿Cuáles son los estados financieros clave de CRISPR Therapeutics AG?

Accepted Answer

Según el último estado financiero (Form-10K), CRISPR Therapeutics AG tiene un total de activos de $2,242, una ganancia neta loss de $-366

Question 2

¿Cuáles son los ratios financieros clave para CRSP?

Accepted Answer

El ratio corriente de CRISPR Therapeutics AG es 7.25, el margen neto es -989.18, las ventas por acción son $0.43.

Question 3

¿Cómo se desglosan los ingresos de CRISPR Therapeutics AG por segmento o geografía?

Accepted Answer

CRISPR Therapeutics AG largest revenue segment is Genome-editing Technology, at a revenue of 37,314,000 in the most earnings release.For geography, Switzerland and United States is the primary market for CRISPR Therapeutics AG, at a revenue of 37,314,000.

Question 4

¿Es rentable CRISPR Therapeutics AG?

Accepted Answer

no, según los últimos estados financieros, CRISPR Therapeutics AG tiene una ganancia neta loss de $-366

Question 5

¿Tiene CRISPR Therapeutics AG alguna deuda?

Accepted Answer

yes, CRISPR Therapeutics AG tiene una deuda de 309

Question 6

¿Cuántas acciones en circulación tiene CRISPR Therapeutics AG?

Accepted Answer

CRISPR Therapeutics AG tiene un total de acciones en circulación de 85.74

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	38	37	371	1	915	0
Revenue Growth (YoY)	-81%	-90%	37,000%	-100%	--	-100%
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	233	183	206	212	102	88
Research & Development	283	320	387	461	438	266
Operating Expenses	516	503	593	674	541	355
Other Non Operating Income (Expenses)	89	103	71	22	6	6
Pretax Income	-484	-362	-150	-650	379	-348
Income Tax Expense	3	3	2	0	1	0
Net Income	-488	-366	-153	-650	377	-348
Net Income Growth	104%	139%	-76%	-272%	-208%	-627%
Shares Outstanding (Diluted)	91.3	84.35	79.22	77.7	80.4	65.9
Shares Change (YoY)	7%	6%	2%	-3%	22%	16%
EPS (Diluted)	-5.34	-4.34	-1.93	-8.36	4.7	-5.29
EPS Growth	91%	124%	-77%	-278%	-189%	-552%
Free Cash Flow	-328	-144	-272	-532	457	-256
Free Cash Flow Per Share	-3.59	-1.7	-3.43	-6.84	5.68	-3.88
Gross Margin	--	--	--	--	--	--
Operating Margin	-1,257.89%	-1,259.45%	-59.83%	-67,300%	40.76%	0%
Profit Margin	-1,284.21%	-989.18%	-41.23%	-65,000%	41.2%	0%
Free Cash Flow Margin	-863.15%	-389.18%	-73.31%	-53,200%	49.94%	0%
EBITDA	-460	-447	-203	-649	391	-345
EBITDA Margin	-1,210.52%	-1,208.1%	-54.71%	-64,900%	42.73%	0%
D&A For EBITDA	18	19	19	24	18	9
EBIT	-478	-466	-222	-673	373	-354
EBIT Margin	-1,257.89%	-1,259.45%	-59.83%	-67,300%	40.76%	0%
Effective Tax Rate	-0.61%	-0.82%	-1.33%	0%	0.26%	0%

CRISPR Therapeutics AG (CRSP) Price

CRSP Stock Price Chart

CRSP Income

Follow-Up Questions